Glioblastoma (GBM) is the most common malignant primary brain tumor of adults and one of the most lethal of all cancers. New therapeutic approaches are needed. Genomic, proteomic and mouse model studies implicate mTOR kinase as a compelling GBM target. The role of mTOR complex 1 in GBM is well recognized;the role of mTOR complex 2 is poorly understood. We present exciting preliminary data demonstrating a critical role for mTORC2 signaling in GBM in promoting therapeutic resistance to rapamycin and demonstrate that inhibition of both mTOR complexes is needed to potently induce GBM tumor cell death. This proposal brings together a highly experienced collaborative team with expertise in GBM signal transduction, mTORC2 biochemistry and GBM in vitro and in vivo models to illuminate the molecular circuitry of mTOR signaling in GBM and to develop and test a novel mTOR kinase inhibitor that inhibits both mTOR signaling complexes. We will apply novel mTOR biochemical assays to genetically defined GBM in vitro and in vivo models and meticulously characterized clinical samples to illuminate the molecular circuitry and functional importance of mTORC2 signaling in GBM. In partnership with Celgene, we will develop and test a novel mTOR kinase inhibitor with potent anti-mTORC1 and mTORC2 activity We will: 1) directly measure mTORC2 activity in genetically defined GBM models and clinical samples and identify upstream activators and downstream effectors of mTORC2;2) determine whether combined inhibition of both mTOR signaling complexes is required to block tumor growth and 3) determine the efficacy of the novel mTOR kinase inhibitor for treatment of GBM patients including identifying patients most likely to benefit from the drug.
The proposed studies challenge current research and clinical practice assumptions about mTOR as a GBM target. They address a major gap in our understanding of mTOR signaling and create a pathway to translation through development and testing of a novel mTOR kinase inhibitor. We anticipate that the results obtained from this proposal will have significant impact on the treatment of GBM patients.
|Cloughesy, Timothy F; Cavenee, Webster K; Mischel, Paul S (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9:1-25|
|Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2014) mTORC2 dictates Warburg effect and drug resistance. Cell Cycle 13:1053-4|
|Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25:364-73|
|Bernhart, Eva; Damm, Sabine; Heffeter, Petra et al. (2014) Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways. Neuro Oncol 16:933-45|
|Nathanson, David A; Gini, Beatrice; Mottahedeh, Jack et al. (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-6|
|Gini, Beatrice; Mischel, Paul S (2014) Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discov 4:876-8|
|Akhavan, David; Pourzia, Alexandra L; Nourian, Alex A et al. (2013) De-repression of PDGFR* transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 3:534-47|
|Wang, Jun; Hwang, Kiwook; Braas, Daniel et al. (2013) Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. J Nucl Med 54:1820-4|
|Iwanami, Akio; Gini, Beatrice; Zanca, Ciro et al. (2013) PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A 110:4339-44|
|Babic, Ivan; Mischel, Paul S (2013) Multiple functions of a glioblastoma fusion oncogene. J Clin Invest 123:548-51|
Showing the most recent 10 out of 19 publications